Filing Details
- Accession Number:
- 0001022079-22-000168
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2022-11-29 16:35:10
- Reporting Period:
- 2022-11-28
- Accepted Time:
- 2022-11-29 16:35:10
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1022079 | Quest Diagnostics Inc | DGX | Services-Medical Laboratories (8071) | 161387862 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1520897 | T. Catherine Doherty | 500 Plaza Drive Secaucus NJ 07094 | Svp, Regional Businesses | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2022-11-28 | 40,765 | $86.63 | 108,498 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2022-11-28 | 17,358 | $148.92 | 91,140 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2022-11-28 | 23,407 | $149.37 | 67,733 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Non-Qualifed Stock Option (right to buy) | Disposition | 2022-11-28 | 40,765 | $86.63 | 40,765 | $86.63 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | 2029-02-18 | No | 4 | M | Direct |
Reported Non-Derivative Holdings
| Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
|---|---|---|---|
| Common Stock | 4,226 | Indirect | 401(k)/SDCP |
Footnotes
- The sale reported was effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person on October 27, 2022.
- This transaction was executed in multiple trades at prices ranging from $148.120 to $149.110. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- This transaction was executed in multiple trades at prices ranging from $149.120 to $149.860. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- These underlying shares were acquired on a periodic basis by the trustee of the Company's tax qualified Profit Sharing (401(k)) and/or Supplemental Deferred Compensation Plan. The information was obtained from the plan administrator as of a current date. The number of shares is based on the account balance of the Company stock fund under each Plan (which includes some money market instruments) divided by the market price of the Company's stock as of that date.
- The options vested in three annual installments beginning with the first on February 18, 2020, the second on February 18, 2021 and the final on February 18, 2022.
Billionaire Hedge Funds
